Contingent Consideration - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			2 Months Ended	3 Months Ended
	Nov. 19, 2020	Jul. 12, 2019	Nov. 19, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Estimated future contingent consideration				$ 4,310	$ 6,270	$ 6,090	$ 5,390
Change in value of contingent consideration for acquired in-process research and development				$ (1,780)	$ 880
Regulatory milestone achieved				0
Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Up-front consideration	$ 13,600
Shares issued for contingent milestone payment	1,694,906
Period for submission of clinical trial notification	60 days
Submission date of clinical trial notification	Oct. 29, 2020
Clinical Trial Notification [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Change in value of contingent consideration for acquired in-process research and development			$ 5,400
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date		Jul. 08, 2019
Unregistered shares of common stock		1,887,250
Up-front consideration		$ 5,000
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration		$ 5,000
Estimated future contingent consideration term		60 days
Number of consecutive trading days		20 days
Consideration amount		$ 2.95
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration		$ 3,000
Estimated future contingent consideration term		60 days
Number of consecutive trading days		20 days
Consideration amount		$ 3.54
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration		$ 80,000
License agreement term		10 years
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Upfront consideration release at 3 months		50.00%
Upfront consideration release at 9 months		50.00%
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Consideration amount	$ 9.57		$ 9.57
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration		$ 88,000